Dosage Forms & Drug Delivery Systems – Page 49

E&L Failure during EMA/MHRA review: batch release impact and documentation pack

Identifying symptoms or signals of potential E&L failures is the first step in an effective deviation investigation. Common indications might include:Click to read the full article.

E&L Failure during FDA inspection: what inspectors expect and how to fix it

E&L Study Failures: Strategies to Satisfy FDA Inspectors Extractables and leachables (E&L) testing has become an integral part of pharmaceutical manufacturing, particularly in relation to product safety and regulatory compliance.…

Leakage Complaint during EU/UK launch supply: FDA/MHRA investigation and corrective actions

Identifying symptoms of a leakage complaint is the first critical step in addressing the issue effectively. Symptoms may stem from various sources, including quality control indicators, customer feedback, or direct…

Risk Management File Gap during FDA inspection: what inspectors expect and how to fix it

Recognition of symptoms or signals that suggest a risk management file gap is critical in maintaining regulatory compliance. The following are key indicators:Click to read the full article.

Dhf Missing during lifecycle management: batch release impact and documentation pack

Missing DHF documents can manifest in various scenarios. Here are some symptoms that may indicate a compliance breach or operational inefficiency:Click to read the full article.

Device-Drug Compatibility Failure in DPI manufacturing: E&L risk assessment and documentation

Symptoms of device-drug compatibility failure can manifest at various points in the manufacturing process or later during stability testing. Recognizing these early signs is crucial for prompt investigation. Here are…

Complaint Handling Deficiency during PAI readiness: what inspectors expect and how to fix it

Understanding the initial symptoms or signals are critical to identifying complaint handling deficiencies. Typical issues may manifest as:Click to read the full article.

E&L Failure for drug-device combination products: what inspectors expect and how to fix it

Identifying the symptoms or signals of E&L failures is a vital first step in any investigation. Symptoms can manifest in various forms, including consumer complaints, quality control (QC) deviations, and…

Gmp Gap for drug-device combination products: risk assessment and change control template

The initial indication of a potential GMP gap in drug-device combination products often manifests in various symptoms or signals within the manufacturing environment. These may include:Click to read the full…

Apsd Oos in DPI manufacturing: device qualification and assembly controls

The first step in addressing an Apsd OOS incident is recognizing the symptoms or signals that indicate a potential issue. This may include:Click to read the full article.

Oos Investigation during tech transfer: ownership between drug GMP and device QMS

The first step in any OOS investigation during tech transfer is to recognize the signals that indicate a potential problem. These symptoms can manifest in various forms, and catching them…

Dhf Missing during FDA inspection: batch release impact and documentation pack

The initial indication of a potential issue related to missing DHF often comes from various signals observed on the manufacturing floor or within the quality control laboratory. These may include:Click…